PVI
GRCE

Pura Vida Investments’s Grace Therapeutics GRCE Stock Holding History

Pura Vida Investments’s Portfolio GRCE Stock Details GRCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-6,940
Closed -$380K – 126
2019
Q2 		$380K Buy
6,940
+2,605
+60% +$114K 0.06% 95
2019
Q1 		$212K Buy
4,335
+413
+11% +$20.4K 0.03% 102
2018
Q4 		$157K Buy
+3,922
New +$171K 0.03% 73

Other funds holding GRCE

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
PP
Peconic Partners New York $5.78B AUM 127.23% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $304B AUM 35.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
MFS
Monetta Financial Services Wheaton, Illinois $148M AUM 75.79% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
OC
Oppenheimer & Co New York $9.37B AUM 36.4% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
MMPW
Mitchell McLeod Pugh & Williams Mobile, Alabama $815M AUM 30.42% 1-Year Est. Return

Pura Vida Investments's GRCE Position: Q3 2019 in Review

Pura Vida Investments sold out of Grace Therapeutics (GRCE) in Q3 2019, closing a stake of 6,940 shares — an estimated $380K sold.

Pura Vida Investments first reported a position in GRCE in Q4 2018 and held it in 3 quarters. The position peaked at $380K in Q2 2019. 27 funds tracked by Wall St. Rank hold GRCE as of Q3 2019.

  • Pura Vida Investments reported no remaining Grace Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Pura Vida Investments sold 6,940 Grace Therapeutics shares in Q3 2019, an estimated $380K.
  • Pura Vida Investments first reported a position in Grace Therapeutics in Q4 2018 and held it in 3 quarters.
  • Pura Vida Investments's Grace Therapeutics position peaked at $380K in Q2 2019.
  • 27 funds tracked by Wall St. Rank held Grace Therapeutics as of Q3 2019.

Based on Pura Vida Investments's 13F filing for Q3 2019, filed 14 Nov 2019.